Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.

[1]  R. DiPaola,et al.  Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. , 2018, European urology.

[2]  N. Lumen,et al.  Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial. , 2018, Urologic oncology.

[3]  M. Parmar,et al.  Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Thomas Wiegel,et al.  Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. , 2018, European urology.

[5]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Boorjian,et al.  Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. , 2017, European urology.

[7]  H. G. van der Poel,et al.  Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard. , 2017, European urology.

[8]  M. Parmar,et al.  Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis , 2017, European journal of cancer.

[9]  Mason,et al.  LBA33What are the optimal systemic treatments for men with metastatic, hormone-sensitive prostate cancer? A STOPCaP systematic review and network meta-analysis , 2017 .

[10]  M. Sydes,et al.  LBA31_PRAdding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Directly randomised data from STAMPEDE (NCT00268476) , 2017 .

[11]  Y. Park,et al.  Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer , 2017, The New England journal of medicine.

[12]  M. Parmar,et al.  Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy , 2017, The New England journal of medicine.

[13]  A. Ramos-Esquivel,et al.  Androgen-deprivation therapy plus chemotherapy in metastatic hormone-sensitive prostate cancer. A systematic review and meta-analysis of randomized clinical trials. , 2016, Urologic oncology.

[14]  S. Culine,et al.  Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. , 2016, European urology.

[15]  U. Ferreira,et al.  Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis , 2016, PloS one.

[16]  Yucai Wang,et al.  Docetaxel in the treatment of metastatic hormone-sensitive and castration-resistant prostate cancer: A meta-analysis. , 2016 .

[17]  D. Cella,et al.  Quality of life (QOL) analysis from CHAARTED: Chemohormonal androgen ablation randomized trial in prostate cancer (E3805). , 2016 .

[18]  I. Ahmad,et al.  Androgen deprivation therapy alone or with docetaxel in hormone naive metastatic prostate cancer: Meta-analysis of randomized phase III trials. , 2016 .

[19]  G. Scagliotti,et al.  Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. , 2016, European urology.

[20]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[21]  I. Tannock,et al.  Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  M. Parmar,et al.  Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data , 2016, The Lancet. Oncology.

[23]  L. Gianni,et al.  Chemotherapy in metastatic hormone-naïve prostate cancer: Pooled analysis of randomized clinical trials. , 2016 .

[24]  A. Ramos-Esquivel,et al.  Androgen-deprivation therapy plus docetaxel-based chemotherapy in metastatic hormone-sensitive prostate cancer. A meta-analysis of randomized clinical trials. , 2016 .

[25]  A. Horwich,et al.  Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[27]  Kristian Thorlund,et al.  The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations , 2015, Annals of Internal Medicine.

[28]  C. Mullins,et al.  Understanding heterogeneity of treatment effect in prostate cancer , 2015, Current opinion in oncology.

[29]  Thomas Wiegel,et al.  Guidelines on Prostate Cancer , 2013 .

[30]  J. Robins,et al.  Correcting for Noncompliance and Dependent Censoring in an AIDS Clinical Trial with Inverse Probability of Censoring Weighted (IPCW) Log‐Rank Tests , 2000, Biometrics.